Andrew Artz MD- Hematologist-Oncologist- City Of Hope
Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the topic’s extensive coverage. Playfully, he considers sharing random pictures or dinner plans but proceeds to discuss his presentation’s content. He highlights the increasing use of allogeneic transplants, especially for older patients and those in first remission, attributing this rise to novel therapies. Dr. Artz emphasizes the challenge of relapse and the need to balance it against transplant-related toxicities.
Shifting to transplantation intensity, he compares myeloablative regimens with lower-intensity options, noting the potential benefits of higher intensity despite challenges. He mentions targeted radiation’s promise for reducing extramedullary toxicity. Dr. Artz addresses post-transplant maintenance therapy, discussing trials involving agents like azacitidine, sorafenib, and gilteritinib, underscoring the importance of considering MRD status and genetic factors. He concludes by advocating personalized transplant strategies, considering relapse risk and treatment-related mortality, and endorsing continued research and clinical trials.